Group 1 - The core viewpoint of the news is that Xinmai Medical has seen a continuous increase in its stock price, with a 7.53% rise over three days, reaching 99.25 CNY per share, and a total market capitalization of 12.234 billion CNY [1] - Xinmai Medical, established on August 17, 2012, and listed on July 22, 2019, specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1] - The company's main business revenue composition is as follows: 71.94% from aortic products, 28.04% from peripheral and other products, and 0.02% from other sources [1] Group 2 - According to data from the top ten holdings of funds, one fund under Xinhua Fund holds shares in Xinmai Medical, specifically the Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund (001294), which has maintained its holding of 24,700 shares [2] - The fund's holding represents 4.28% of its net asset value and is the eighth largest holding, with a floating profit of approximately 40,000 CNY today and 171,700 CNY during the three-day increase [2] - The Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund was established on June 29, 2015, with a latest scale of 52.9542 million CNY, and has achieved a year-to-date return of 3.07% [2]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd. (referred to as "Tuomai Medical"), has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The product represents a significant advancement in the company's medical device offerings [1]

Group 1 - The core point of the article is that Shanghai MicroPort MedBot (Group) Co., Ltd.'s wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its product "Polyvinyl Alcohol Embolization Microspheres" [1] Group 2 - The product "Polyvinyl Alcohol Embolization Microspheres" is a new medical device aimed at enhancing treatment options in the healthcare sector [1]

FinderSphere®/夜明珠™聚乙烯醇栓塞微球是公司在肿瘤介入治疗领域研发 的首款栓塞类产品。该产品将为 TACE 手术提供更精准、更高效的治疗方案选 择，使国内更多肿瘤患者受益。除该款产品，公司在肿瘤介入治疗领域已有 Tipspear®/穿云箭™经颈静脉肝内穿刺套件在国内获批上市，在研产品包括国家创 新医疗器械 HepaFlow®/鹊桥通™TIPS 覆膜支架系统，以及封堵止血系统、微导 管等多款产品。未来，公司将继续致力于主动脉、外周血管及肿瘤介入高端医疗 器械的创新研发和应用推广，让更多国内外患者获益。 三、风险提示 鉴于上述产品需要获得生产许可证后方可上市销售，此外，产品上市后的实 际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未来营 业收入的具体影响。敬请投资者理性投资，注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗" 或"公司"）的全资子公司上海拓脉医疗科技有限公司（以下简称"拓脉医疗"） 获得国家药品监督 ...

Core Viewpoint - The company, Xinmai Medical (688016.SH), has received a medical device registration certificate from the National Medical Products Administration for its polyethylene glycol embolization microspheres, marking a significant advancement in interventional oncology treatment options [1] Group 1: Product Development - The polyethylene glycol embolization microspheres, named FinderSphere®/Night Pearl™, are the company's first embolization product developed for interventional oncology [1] - This product aims to provide more precise and efficient treatment options for Transarterial Chemoembolization (TACE) procedures, benefiting a larger number of cancer patients in China [1] Group 2: Existing and Pipeline Products - In addition to the new product, the company has already launched the Tipspear®/Piercing Arrow™ transjugular intrahepatic portosystemic shunt (TIPS) kit in China [1] - The company is also developing several other products in the interventional oncology field, including the innovative medical device HepaFlow®/Bridge to the Sky™ TIPS covered stent system, as well as hemostatic occlusion systems and microcatheters [1] Group 3: Future Commitment - The company is committed to the innovative research and application promotion of high-end medical devices in aortic, peripheral vascular, and interventional oncology fields, aiming to benefit more patients both domestically and internationally [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tuomai Medical, has received a medical device registration certificate from the National Medical Products Administration for a polyethylene glycol embolization microsphere, marking a significant advancement in the company's interventional oncology product line [1] Group 1 - The registration certificate number is Guo Xie Zhu Ren 20263130187, valid from January 28, 2026, to January 27, 2031 [1] - The product is classified as a Class III medical device, intended for embolization treatment of hypervascular malignant tumors in solid organs [1] - This product represents the company's first embolization product in the field of tumor interventional therapy, potentially offering improved treatment options [1] Group 2 - The product must obtain a production license before it can be sold, and the sales situation remains uncertain, making it difficult to predict its impact on revenue [1]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The subsidiary involved in this development is Shanghai Tuomai Medical Technology Co., Ltd. [1]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

Group 1 - The core viewpoint of the news is that Xinmai Medical has experienced fluctuations in its stock performance and financing activities, indicating a mixed market sentiment towards the company [1][2]. - On February 2, Xinmai Medical's stock fell by 2.87%, with a trading volume of 154 million yuan, and a net financing purchase of 9 million yuan, suggesting a cautious investor approach [1]. - As of February 2, the total balance of margin trading for Xinmai Medical was 482 million yuan, with a financing balance of 479 million yuan, representing 4.21% of its market capitalization, which is below the 20th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for Xinmai Medical decreased by 8.73% to 16,000, while the average circulating shares per person increased by 9.56% to 7,708 shares [2]. - For the period from January to September 2025, Xinmai Medical reported a revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, but the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2]. - The company has distributed a total of 1.079 billion yuan in dividends since its A-share listing, with 817 million yuan distributed over the past three years [2].

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the third quarter of 2025 [2] - As of January 29, 2026, Xinmai Medical's stock closed at 94.72 yuan, with a slight increase of 0.77% and a trading volume of 21,600 shares, resulting in a total transaction amount of 204 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 12.5 million yuan, accounting for 6.11% of the total transaction amount, while retail investors saw a net inflow of 6.98 million yuan, representing 3.41% of the total [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 alone saw a significant revenue increase of 64.68% year-on-year, reaching 300 million yuan, although the net profit for that quarter fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85%, with investment income reported at 11.6 million yuan and a gross profit margin of 70.4% [2]